FibroGen, Inc - stock earnings
FGEN Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 6, 2024 AfterMarket | -0.33 / -0.43 | - | 55.9 million / 37.4 million | - |
FGEN Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -56.2 million USD | 27.1 million USD |
| 2023Q3 | -63.6 million USD | 40.1 million USD |
| 2023Q2 | -87.7 million USD | 44.3 million USD |
| 2023Q1 | -77.5 million USD | 36.2 million USD |
| 2022Q4 | -66.5 million USD | 34.4 million USD |
| 2022Q3 | -92.1 million USD | 15.7 million USD |
| 2022Q2 | -73.2 million USD | 29.8 million USD |
| 2022Q1 | -63.5 million USD | 60.8 million USD |
| 2021Q4 | -134.1 million USD | 16.5 million USD |
| 2021Q3 | 49.8 million USD | 156.0 million USD |
| 2021Q2 | -134.0 million USD | 24.4 million USD |
| 2021Q1 | -71.8 million USD | 38.4 million USD |
| 2020Q4 | -58.6 million USD | 65.0 million USD |
| 2020Q3 | 33.0 million USD | 44.0 million USD |
| 2020Q2 | -85.3 million USD | 42.9 million USD |
| 2020Q1 | -78.3 million USD | 24.4 million USD |
| 2019Q4 | -98.1 million USD | 8.0 million USD |
| 2019Q3 | -49.4 million USD | 33.2 million USD |
| 2019Q2 | 116.0 million USD | 191.6 million USD |
| 2019Q1 | -45.4 million USD | 23.9 million USD |
| 2018Q4 | 21.0 million USD | 108.1 million USD |
| 2018Q3 | -42.6 million USD | 29.0 million USD |
| 2018Q2 | -23.4 million USD | 44.0 million USD |
| 2018Q1 | -41.4 million USD | 31.9 million USD |
| 2017Q4 | -22.1 million USD | 42.5 million USD |
| 2017Q3 | -37.7 million USD | 27.3 million USD |
| 2017Q2 | -33.2 million USD | 29.0 million USD |
| 2017Q1 | -33.2 million USD | 26.9 million USD |
| 2016Q4 | -34.0 million USD | 31.9 million USD |
| 2016Q3 | -24.2 million USD | 30.1 million USD |
| 2016Q2 | 24.3 million USD | 89.3 million USD |
| 2016Q1 | -27.8 million USD | 28.3 million USD |
| 2015Q4 | -51.4 million USD | 24.4 million USD |
| 2015Q3 | -45.1 million USD | 19.5 million USD |
| 2015Q2 | 57.1 million USD | 120.6 million USD |
| 2015Q1 | -46.4 million USD | 16.3 million USD |
| 2014Q4 | -50.6 million USD | 16.1 million USD |
| 2014Q3 | -39.5 million USD | 13.7 million USD |
| 2014Q2 | 46.8 million USD | 90.0 million USD |
| 2014Q1 | -16.2 million USD | 17.9 million USD |
| 2013Q4 | -26.8 million USD | 12.4 million USD |
| 2013Q3 | 39.3 million USD | 71.2 million USD |
| 2012Q4 | ? USD | 65.9 million USD |
FGEN Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -284.2 million USD | 147.8 million USD |
| 2022 | -295.2 million USD | 140.7 million USD |
| 2021 | -291.0 million USD | 235.3 million USD |
| 2020 | -189.3 million USD | 176.3 million USD |
| 2019 | -77.0 million USD | 256.6 million USD |
| 2018 | -86.4 million USD | 213.0 million USD |
| 2017 | -126.2 million USD | 125.7 million USD |
| 2016 | -61.7 million USD | 179.6 million USD |
| 2015 | -85.8 million USD | 180.8 million USD |
| 2014 | -59.5 million USD | 137.6 million USD |
| 2013 | -14.9 million USD | 102.2 million USD |
| 2012 | -32.6 million USD | 65.9 million USD |
FGEN
Price: $1.13
52 week price:
Payout Ratio Range:
Earnings Per Share: -2.92 USD
P/E Ratio: -0.89
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.0 million
Ebitda: -33.4 millionMarket Capitalization: 136.3 million